News

Penumbra’s Newest Generation of Indigo Aspiration System Receives FDA Clearance for Pulmonary Embolism
November 20, 2020
…
ESC: Social Isolation During COVID-19 Pandemic Linked With High Blood Pressure
November 19, 2020
Buenos Aires, Argentina, November 19, 2020:  Lockdown due to the COVID-19 pandemic is associated with an increase in high blood pressure among patients admitted to emergency. That’s the finding of a study presented at the 46th Argentine Congress of Cardiology (SAC).
Mount Sinai Cardiologist Awarded $2.9 Million NIH Grant to Advance Work with Stem Cells and Heart Repair after Heart Attack
November 19, 2020
Research may lead to identifying novel therapies for cardiac patients
Milestone Pharmaceuticals Announces First Patient Enrolled in RAPID, a Pivotal Phase 3 Study of Etripamil in PSVT
November 19, 2020
- RAPID and completed NODE-301 studies could potentially fulfill efficacy requ
Medtronic's ABRE Stent: Vascular Surgeon Performs First-in-the-Country Commercial Procedure at Sanger Heart & Vascular Institute
November 18, 2020
November 18, 2020 — Deep vein blockages impact more than 27 million people worldwide. For years, many people suffering from venous disease didn’t have access to advanced treatment options.
Mount Sinai Heart Awarded Transcatheter Valve Certification by American College of Cardiology
November 18, 2020
Only program in New York City to receive prestigious recognition 
SCCT and NASCI Release New Expert Consensus Document on Coronary CT Imaging of Atherosclerotic Plaque
November 17, 2020
Arlington, VA (November 17, 2020) — The Society of Cardiovascular Computed Tomography (SCCT), in collaboration with the North American Society of Cardiovascular Imaging (NASCI), has released a new 
Radiation Protection: Burlington Medical Introduces 3DLOOK, an Industry-First Self-Service, Body-Scanning Technology
November 17, 2020
This cutting-edge technology supports Burlington’s made-to-measure capabilities without the need for in-person fittings.  
AHA: Investigational Drug Finerenone Helps Heart Health in People With Chronic Kidney Disease, Type 2 Diabetes
November 17, 2020
DALLAS, Nov. 17, 2020 -- The investigational medication finerenone reduced the risk of heart attack, stroke, heart failure and other negative cardiovascular events in patients with chronic kidney disease and Type 2 diabetes, according to late-breaking research presented at the American Heart Association's Scientific Sessions 2020.
AHA: Diabetes Drug Can Treat and Reverse Heart Failure and Reduce Hospitalizations
November 16, 2020
Mount Sinai clinical trial results could help lead to FDA approval (New York, NY – November 16, 2020) – Empagliflozin, a recently developed diabetes drug, can effectively treat and reverse heart failure in both diabetic and non-diabetic patients, according to researchers at the Icahn School of Medicine at Mount Sinai.